PPARG and Alzheimer disease: In recent years, the neuroprotective effects of PPARγ agonists has been assessed in several in vitro and in vivo models of several neurodegenerative conditions including PD [33, 34], Alzheimer’s disease [35, 36], cerebral ischemia [37] and amyotrophic lateral sclerosis [38].